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Keypoints 
 
 HCK transcription and activation is triggered by mutated MYD88, and is an 
important determinant of pro-survival signaling.  
 HCK is also a target of ibrutinib, and inhibition of its kinase activity triggers 
apoptosis in mutated MYD88 cells. 
 
Abstract 
 
Activating mutations in MYD88 are present in approximately 95% of patients with 
Waldenstrom Macroglobulinemia (WM), as well as other B-cell malignancies 
including ABC DLBCL. In WM, mutated MYD88 triggers activation of BTK. 
Ibrutinib, a pleiotropic kinase inhibitor that targets BTK, is highly active in patients 
with mutated MYD88. We observed that mutated MYD88 WM and ABC DLBCL 
cell lines, as well as primary WM cells show enhanced HCK transcription and 
activation, and that HCK is activated by IL6. Over-expression of mutated MYD88 
triggers HCK and IL6 transcription, while knockdown of HCK reduced survival and 
attenuated BTK, PI3K/AKT, and MAPK/ERK signaling in mutated MYD88 WM 
and/or ABC DLBCL cells. Ibrutinib and the more potent HCK inhibitor A419259 
blocked HCK activation and induced apoptosis in mutated MYD88 WM and ABC 
DLBCL cells. Docking and pull-down studies confirmed that HCK was a target of 
ibrutinib. Ibrutinib and A419259 also blocked ATP binding to HCK, while 
transduction of mutated MYD88 expressing WM cells with a mutated HCK 
gatekeeper greatly increased the EC50 for ibrutinib and A419259. The findings 
support that HCK expression and activation is triggered by mutated MYD88, 
supports the growth and survival of mutated MYD88 WM and ABC DLBCL cells, 
and is a direct target of ibrutinib. HCK represents a novel target for therapeutic 
development in MYD88 mutated WM and ABC DLBCL, and possibly other 
diseases driven by mutated MYD88. 
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Introduction 
 
Next generation sequencing has revealed activating MYD88 mutations in several 
B-cell malignancies. Particularly striking has been the expression of MYD88 
mutations in Waldenstrom Macroglobulinemia (WM), wherein 95-97% of patients 
express MYD88L265P, and more rarely non-L265P MYD88 mutations.1-4 Up to 30% 
of patients with activated B-cell (ABC) subtype of diffuse large B-cell lymphoma 
(ABC DLBCL) also express activating MYD88 mutations, including MYD88L265P.5,6 
Mutations in MYD88 promote Myddosome self-assembly and can trigger NF-kB 
signaling in the absence of Toll (TLR) or IL1 (IL1R) receptor signaling through IL1 
Receptor Associated Kinases (IRAK4/IRAK1) or Bruton’s Tyrosine Kinase 
(BTK).5,7 
 
Ibrutinib is a pleiotropic kinase inhibitor that is known to target BTK, and is highly 
active in previously treated WM patients producing an overall response rate of 
91%.8 In WM patients, both major and overall responses to ibrutinib are higher in 
patients with MYD88 mutations.9 CXCR4 WHIM mutations that are present in up 
to 40% of WM patients can also impact ibrutinib response.4 Ibrutinib also shows 
activity in previously treated patients with ABC-DLBCL, particularly among 
patients with BCR pathway and MYD88 mutations.10 Ibrutinib is also active in 
other B-cell malignancies including CLL and MCL. Suppression of tonic B-cell 
receptor (BCR) activity mediated by BTK has been implicated as the mechanism 
underlying ibrutinib activity in non-WM B-cell diseases.  
 
In addition to BTK, ibrutinib can suppress the activity of several other kinases 
including members of the SRC family.11 Hematopoietic cell kinase (HCK) is a 
member of the SRC family of protein tyrosine kinases, and one of the most 
aberrantly up-regulated genes in WM cells.12 In myeloma cells, HCK is activated 
by interleukin 6 (IL6) through the IL6 co-receptor IL6ST (GP130).13,14 IL6 is also a 
potent growth and survival factor in WM, though the functional significance of 
HCK in WM pathogenesis remains unclear.15 We therefore investigated the role of 
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HCK in WM, and impact of MYD88 mutations and ibrutinib on the transcriptional 
regulation and activation of this SRC family member. 
 
Materials and Methods 
 
Primary cells and cell lines 
 
Primary WM cells (CD19+) were isolated from bone marrow (BM) aspirates, and 
peripheral blood mononuclear cells (PBMC) were collected from healthy donors 
(HD) after informed written consent. Primary WM lymphoplasmacytic cells (LPC) 
and cell lines were genotyped for MYD88 and CXCR4 mutations as previously 
described.2,4 MYD88L265P BCWM.1 and MWCL-1 WM cells; TMD-8, HBL-1, and 
OCI-Ly3 and MYD88S122R SU-DHL2 ABC DLBCL cells; and MYD88 wild-type 
(MYD88WT) OCI-Ly7 and OCI-Ly19 germinal center B-cell (GCB) DLBCL cells; 
Ramos Burkitt’s cells; and RPMI-8226 and MM.1S myeloma cells were used.  
 
Lentiviral transduction experiments 
 
MYD88WT or MYD88L265P proteins were over-expressed in BCWM.1 and MWCL-1 
cells following lentiviral transduction as previously described.7 The over-
expression of proteins coding for wild-type HCK (HCKWT) or HCK harboring a 
mutated gatekeeper residue (HCKT333M) at amino acid position 333 (338 based on 
c-SRC numbering)16 was accomplished by lentiviral transduction of HCKWT or 
HCKT333M (r. 1235C>T in NM_002110.3) sequences in a pLVX-EF1α-IRES-Puro 
vector (Clontech Laboratories, Mountain View CA). Knockdown of HCK or IL6ST 
(GP130) was performed using an inducible the lentiviral shRNA expression vector 
pLKO-Tet-On containing a tetracycline regulated expression cassette (Addgene, 
Cambridge MA). Following lentiviral transduction of BCWM.1 and MWCL-1 cells, 
stable cell lines were selected with 0.5~1.0 ug/ml puromycin in tetracycline-free 
medium. For the induced knockdown of HCK or IL6ST, tetracycline (0.8 ug/ml) 
was added to culture media. For HCK knockdown, lentiviral vectors were 
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designed to target 5’-GCTGTGATTTGGAAGGGAA-3’ (HCK shRNA1) and 5’-
GGATAGCGAGACCACTAAA-3’ (HCK shRNA2). IL6ST knockdown targeted 5’-
GGAGCAATATACTATCATA-3’ (IL6ST shRNA1) and 5’-
GGAACTGTCTAGTATCTTA-3’ (IL6ST shRNA2). A scrambled shRNA vector was 
used for control purposes.  
 
Cell viability assessments 
 
Apoptosis analysis was performed using Annexin V/Propidium iodide staining with 
the Apoptosis Detection Kit I (BD Pharmingen, San Jose CA). Cells (1×106/well) 
were treated in 24 well plates for 18 hours with inhibitors or corresponding 
controls. A minimum of 10,000 events were acquired using a BD™ FACSCanto II 
flow cytometer, and analyzed with BD FACS DIVA Software. For WM patient 
cells, BMMC (2×106/well) were treated with inhibitors, and CD19-APC-cy7 
antibody (BD Pharmingen) was used with Annexin V antibody to analyze WM cell 
apoptosis. AlamarBlue® cell viability assay (Life Technologies, Carlsbad CA) was 
used to assess cell death following inducible HCK knockdown. For these 
experiments, transduced cells (1×105/ml) were cultured with tetracycline, and 
aliquoted every other day on days 1-11. AlamarBlue® solution (1/10 total volume) 
was added to cells and incubated for 2 hours. Aliquoted plates were read in a 
SpectraMax M3 plate reader (Molecular Devices, Sunnyvale, CA). Relative cell 
survival was calculated as percentage of fluorescence relative to scrambled 
control. The CellTiter-Glo® Luminescent cell viability assay (Promega, Madison 
WI) was used to assess the dose-response of inhibitors. Cells were seeded into 
384 well plates with the EL406 Combination Washer Dispenser (BioTek 
Instruments, Inc.) and inhibitors injected into the cells culture media with the 
JANUS Automated Workstation (PerkinElmer Inc., Waltham MA). Cells were 
treated with serial diluted inhibitors (20~0.0006μM) for 72 hours at 37o C. 
Luminescent measurement was performed using the 2104 Envision® Multilabel 
Reader (PerkinElmer Inc.).  
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RT-PCR and quantitative-PCR 
 
Total RNA were isolated using AllPrep DNA/RNA Mini Kit (QIAGEN), and cDNA 
synthesized by SuperScript® III First-Strand Synthesis SuperMix (Life 
Technologies). Quantitative detection of mRNA levels for HCK, IL6 and IL6R was 
performed using TaqMan® Gene Expression Assays with TaqMan® Gene 
Expression Master Mix per manufacturer’s instructions using the ABI Prism 7500 
Sequence Detection System (Applied Biosystems). HCK transcription was also 
assessed two hours following incubation with either IL6 (1-10 ng/mL) or IL6 
blocking antibody (1-10 ug/mL) (both from R&D Systems, Minneapolis MN) in 
BCWM.1 and MWCL-1 cells by quantitative RT-PCR.  
 
PhosFlow analysis  
 
PhosFlow analysis was performed to delineate HCK phosphorylation. Cells were 
fixed with BD PhosFlow Fix Buffer I at 37ºC for 10 min. Cells were then 
centrifuged (300×g for 5 min) and washed twice with PhosFlow Perm/Wash Buffer 
I (BD Pharmingen). Cells were then stained with HCK (pTyr411) antibody (Abcam, 
Cambridge MA) alone (for cell lines) or with anti-CD20-APC-Cy7 (BD 
Pharmingen) for primary WM cells. Following staining, cells were incubated in the 
dark for 30 min at room temperature, then washed thrice with BD PhosFlow 
Perm/Wash Buffer I, followed by anti-Rabbit IgG DyLight®-649 secondary 
antibody (Abcam), and incubated for an additional 20 min. Cells were then 
washed twice with BD PhosFlow Perm/Wash Buffer I and flow analysis performed 
using a BD™ FACSCanto II Flow Cytometer.  
 
Immunoblotting  
 
Immunoblotting was performed following gene over-expression, knockdown or 
kinase pulldown with biotinylated probes using antibodies for HCK, AKT-pT308, 
AKT, ERK1/2-pT202/pY204, ERK1/2, PLCγ1-pY783, PLCγ2-pY1217, PLCγ2, 
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BTK-pY223, BTK, IRAK4-pT345/S346, IRAK4, SRC, LYN (Cell Signaling 
Technologies, Danvers MA), PI3K-p85β-pY464 (LifeSpan Biosciences, Seattle 
WA), PI3K-p85β, PLCγ1, IL6ST (Santa Cruz Biotechnology, Dallas TX) in primary 
WM cells, and cell lines. Staining with GAPDH antibodies was used for 
determination of protein loading (Santa Cruz Biotechnology).   
 
Ibrutinib probe assay and kinase active-site inhibition assay 
 
For Ibrutinib probe assay, BCWM.1, MWCL-1 or TMD-8 cells (2×107) were treated 
with ibrutinib-biotin or CC-292-biotin (2 uM) for 1 hour. Cells then washed with 
PBS twice, and lysed with co-IP buffer (Invitrogen, Grand Island NY). Two mg of 
protein from lysed cells was then incubated with 50 ul of Pierce Streptavidin 
Magnetic Beads (Thermo Fisher Scientific, Cambridge MA) at 4ºC for 1 hour, then 
washed with TBST (0.1% Tween-20) thrice, and proteins eluted with SDS-PAGE 
sample buffer. For Kinase active-site inhibition assay, BCWM.1 cells (2×107) were 
pre-treated with DMSO, ibrutinib, CC-292 or A419259 (MedChem Express, 
Monmouth Junction NJ) at various concentrations for 1 hour. Cells then were 
lysed and kinases were pulled down with ATP-biotin using Pierce™ Kinase 
Enrichment Kit (Thermo Fisher Scientific) per manufacturer's instructions. Kinases 
were eluted with SDS-PAGE sample buffer and detected by western blot.  
 
Docking study 
 
The docking studies were performed using AutoDockTools 1.5617, AutoDock 
VINA18 and Open Babel19 software. The lowest calculated Gibbs energy (ΔG) of 
the predicted binding modes indicates stronger binding affinity, and binding 
modes with ΔG lower than -10 kcal are highly probable to be true.  
 
Statistical analysis  
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The statistical significance of differences was analyzed using One-way ANOVA 
with Tukey's multiple comparisons test by Prism software. Differences were 
considered significant when p<0.05. 
 
Results 
 
HCK transcription is driven by mutated MYD88. 
 
To clarify if HCK expression was aberrant in MYD88 mutated cells, we first 
assessed HCK transcription in MYD88 mutated WM and DLBCL cell lines by 
TaqMan® Gene Expression Assay. The results showed that HCK was markedly 
transcribed in MYD88L265P expressing WM (BCWM.1, MWCL-1) and DLBCL 
(TMD-8, HBL-1, OCI-Ly3) cells, but absent or at very low levels in MYD88WT 
(OCI-Ly7, OCI-Ly19, Ramos, MM1.S and RPMI-8226) cells by quantitative RT-
PCR (Figure 1A). Expression of the HCK transcript was also enhanced in SU-
DHL2 cells that carry the MYD88S122R activating mutation. Western blot analysis 
confirmed enhanced HCK protein expression in MYD88 mutated cell lines (Figure 
1A). We next investigated the mRNA levels of HCK in MYD88L265P genotyped 
CD19-sorted primary WM cells using a TaqMan® Gene Expression Assay. We 
compared HCK expression levels to both sorted healthy donor derived non-
memory (CD19+CD27-) and memory (CD19+CD27+) B-cells, given that the later 
represent the B-cell population from where most cases of WM are likely 
derived.20,21 The HCK transcript was elevated in MYD88L265P WM cells versus 
either healthy donor non-memory or memory B-cells (Figure 1B). CXCR4 
mutation status did not impact HCK transcription in primary WM cells (p=0.90 for 
CXCR4 wild-type versus WHIM mutated patients). To clarify if mutated MYD88 
was responsible for enhanced HCK expression, we over-expressed MYD88L265P 
or MYD88WT protein in MYD88L265P BCWM.1 and MWCL-1 cells, and MYD88WT 
OCI-Ly9 and Ramos cells, and assessed for differences in HCK transcription. By 
Western blot analysis, similar levels of exogenous MYD88 protein were detectable 
in MYD88L265P or MYD88WT transduced cells (Figure 1C). The results of these 
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studies showed significantly higher levels of HCK transcript in all four cell lines 
following over-expression of MYD88L265P versus MYD88WT protein (Figure 1C). 
 
IL6 but not IL6R transcription is induced by mutated MYD88.  
 
Since previous work showed that HCK was activated by IL6 via IL6R/IL6ST, we 
investigated the regulatory role of mutated MYD88 on IL6 and IL6R 
expression.13,14 By quantitative RT-PCR, IL6 transcription was markedly higher in 
MYD88L265P expressing WM (BCWM.1, MWCL-1) and DLBCL (TMD-8, HBL-1, 
OCI-Ly3), as well as MYD88S122R expressing SU-DHL2 cells versus MYD88WT 
(OCI-Ly7, OCI-Ly19, Ramos, MM1.S and RPMI-8226) cells (Figure 2A). Similarly, 
IL6R transcription was increased in MYD88 mutated cell lines. Among MYD88WT 
malignant B-cells, IL6R transcription was low or absent, though was highly 
expressed in MYD88WT malignant plasma cells (Figure 2B). By TaqMan® Gene 
Expression Assay, higher IL6 (Figure 2C) and IL6R (Figure 2D) transcription were 
found in MYD88L265P WM samples versus healthy donor non-memory 
(CD19+CD27-) and memory (CD19+CD27+) B-cells. Given these findings, we next 
sought to clarify if MYD88L265P was a driver for IL6 and IL6R transcription. Over-
expression of the MYD88L265P protein induced marked IL6 (Figure 2E), but not 
IL6R (Figure 2F) transcription in MYD88L265P (BCWM.1, MWCL-1) and MYD88WT 
(OCI-Ly9 and Ramos) cells. Conversely, over-expression of MYD88WT protein had 
little or no impact on IL6 or IL6R transcription. 
 
HCK is hyperactive in MYD88 mutated cells, and its activation but not 
transcription is triggered by IL6.  
 
Given the above findings, we next investigated the activation state of HCK in 
MYD88 mutated WM and DLBCL cell lines, and primary WM cells. By PhosFlow 
analysis, HCK showed consistently high phosphorylation levels at the Tyr411 
activation site in mutated MYD88 versus wild-type MYD88 cells (Figure 3A). 
Significantly higher levels of HCK Tyr411 phosphorylation were also observed in 
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primary WM patient samples versus healthy donor non-memory and memory B-
cells (Figure 3B). CXCR4 mutation status was available for 18 of 20 primary WM 
patient samples, and did not impact HCK Tyr411 phosphorylation (p=0.65 for 
CXCR4 wild-type versus WHIM mutated patients). Treatment of mutated MYD88 
WM and DLBCL cell lines and primary WM lymphoplasmacytic cells (LPCs) with 
IL6 augmented HCK activation, with a peak induction of Tyr411 phosphorylation at 
5 minutes following IL6 administration in mutated MYD88 cells (Figure 3C). In 
contrast, little or no effect on HCK Tyr411 phosphorylation was observed following 
IL6 stimulation in MYD88WT cells. Knockdown of IL6ST attenuated HCK activation 
in the presence or absence of IL6, whereas transduction with a control vector had 
little or no impact on HCK activation in MYD88 mutated BCWM.1 cells (Figure 
3D). Lastly, HCK transcription was not significantly altered following incubation 
with either IL6 (1-10 ng/mL) or an IL6 blocking antibody (1-10 ug/mL) for two 
hours in BCWM.1 and MWCL-1 cells using RT-PCR (data not shown).  
 
HCK is a determinant of survival in MYD88 mutated cells 
We next evaluated the impact of HCK expression on survival in MYD88 mutated 
BCWM.1 and MWCL-1 WM and TMD-8 and HBL-1 ABC DLBCL cells. Successful 
knockdown of HCK was accomplished by lentiviral transduction using inducible 
shRNA vectors (Figure 4A). The results of these studies showed that knockdown 
of HCK in all 4 MYD88 mutated cell lines by either of two shRNA vectors resulted 
in sustained reduction in tumor cell viability over the 9 day evaluation period in 
contrast to cells transduced with a control vector (Figure 4B).  
HCK triggers pro-survival signaling in MYD88 mutated WM cells. 
In view of the above findings, we next interrogated HCK dependent survival 
signaling in MYD88 mutated WM cells. We focused our efforts on PI3K/AKT, 
MAPK and BTK signaling pathways given their established importance in WM 
survival, as well as previous work implicating HCK as an upstream regulator for 
their signaling.22-25 Transduction of HCK in IL6 producing BCWM.1 and MWCL-1 
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cells led to higher HCK protein levels by Western blot analysis and detection of 
activated HCK (Tyr411) by PhosFlow analysis (Figure 5A, 5B). Transduction of 
HCK in BCWM.1 and MWCL-1 cells also triggered PI3K/AKT (pPIK3R2, pAKT), 
MAPK (pPLC1, pERK1/2), and BTK (pBTK, pPLC2) signaling (Figure 5B), 
whereas knockdown of HCK in BCWM.1 and MWCL-1 cells showed a reciprocal 
pattern, with diminished PI3K/AKT, MAPK and BTK signaling (Figure 5C). IRAK4 
activation was not impacted by either HCK over-expression or knockdown. Total 
protein levels for these signaling molecules, and GAPDH remained unchanged in 
these experiments. 
 
Ibrutinib binds to the ATP-binding pocket of HCK and blocks ATP binding.  
 
Kinase selectivity profiling has established that in addition to being a covalent 
inhibitor of BTK, ibrutinib is also a potent non-covalent inhibitor of several SRC 
family members including HCK, YES and LCK.11 We focused our attention on 
investigating the potential functional significance of HCK to ibrutinib’s 
pharmacology due to its structural similarity with A419259, a HCK inhibitor with 
established activity in murine tumor models.16 Indeed both ibrutinib and A419259 
were developed based on the 4-amino-5,7-substituted pyrrolopyrimidine scaffold 
of the classical SRC-family inhibitor: PP1.26 To create a model for how ibrutinib 
might bind to HCK we performed a molecular docking studies of ibrutinib into the 
co-crystal structure of HCK with A419259 (RK-20449) (PDB 3VS3)27 (Figure 6A). 
As expected, the docking study predicts that ibrutinib recognizes the ATP-binding 
pocket of HCK with an almost identical pose as A419259 with a calculated affinity 
energy (ΔG) of -10.5 kcal/mol. Similar to A419259, ibrutinib’s 4-amino group, 
forms a H-bond to the carbonyl groups of the gatekeeper residue Thr333 (Thr338 
based on c-SRC numbering)16 and also with Glu334 of HCK; its 3-nitrogen atom, 
as an H-bond acceptor, interacts with the backbone amino group of Met336 of HCK 
(Figure 6A). The 4-phenoxyphenyl substituent at 5-postion of ibrutinib, which is 
also identical to the 5-substituent of A419259, extends into the inner ATP-
hydrophobic pocket of HCK. The pyrrolidine group at the 7-position of ibrutinib, 
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the only distinctive substituent related to A419259, is predicted to interact with 
Ala390, Asn391 or Asp404 of HCK, whereas the 7-substituent of A419259 protrudes 
outward the ATP-pocket and interacts with Asp348 (Figure 6A). 
 
To confirm HCK target engagement in cells by ibrutinib, we synthesized a biotin 
modified version of ibrutinib.  For comparative purposes we also prepared a 
biotin-modifed version of CC-292, a pyrimidine-based covalent BTK inhibitor.28 
Both ibrutinib and CC-292 use an acrylamide-moeity to form a covalent bond to 
Cys481 and are potent kinase inhibitors of BTK (reported apparent IC50  <0.5 
nM).11,28 Ibrutinib reversibly inhibits the kinase activity of HCK with an IC50 of 3.7 
nM, while CC-292 is a very weak HCK inhibitor with an IC50 of 14.6 μM which is 
well above the observed physiological concentrations of this drug.11,28 As 
expected, biotinylated ibrutinib and CC-292 pulled down BTK in mutated MYD88 
expressing BCWM.1, MWCL-1 and TMD-8 cells demonstrating their ability to 
directly bind to BTK (Figure 6B). Biotinylated ibrutinib, but not CC-292 pulled 
down HCK in MYD88 mutated BCWM.1, MWCL-1 and TMD-8 cells thereby 
confirming binding of ibrutinib to HCK (Figure 6B). 
 
To confirm target engagement in living cells, we performed KiNativ profiling where 
the ability of inhibitors to protect kinases from subsequent labeling with a reactive 
ATP-biotin probe is determined.29 Living cells were treated with either ibrutinib, 
CC-292 or A419259, followed by lysis treatment with ATP-biotin and western 
blotting for BTK, HCK and other SRC family kinases. Consistent with the 
biochemical kinase assays, Ibrutinib and A419259, but not CC-292 blocked ATP 
binding to HCK in a dose-dependent manner, while ibrutinib and CC-292 but not 
A419259 blocked ATP binding to BTK in BCWM.1 WM cells. Consistent with its 
known activity, A419259 also blocked ATP binding to the SRC family members 
SRC and LYN. Conversely, ibrutinib and CC-292 did not block ATP binding to 
either SRC or LYN (Figure 6C). 
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HCK activity is blocked by ibrutinib and impacts survival of MYD88 mutated 
WM cells.  
 
To assess the impact of ibrutinib and A419259 on HCK related activity in MYD88 
mutated WM and ABC DLBCL tumor cells, we performed PhosFlow studies and 
assessed changes in HCK activation (Tyr411). We also evaluated tumor cell 
viability by the CellTiter-Glo® Luminescent cell viability assay, and apoptosis by 
propidium iodide and Annexin V staining to determine if HCK inhibition contributed 
to WM cell death. We observed that ibrutinib, and even more so A419259, 
reduced HCK Tyr411 phosphorylation in MYD88 L265P expressing WM and ABC-
DLBCL cell lines, as well as primary WM LPC. In contrast, CC-292 had little or no 
impact on HCK Tyr411 phosphorylation (Figure 7A). Decreased dose-dependent 
viability was also observed for ibrutinib and more so for A419259 that was more 
pronounced in mutated MYD88 versus MYD88WT cells (Figure 7B). In contrast, 
the BTK inhibitor CC-292 that lacks HCK kinase inhibition showed higher EC50 (>1 
log-fold) for the mutated MYD88 cell lines, with the exception of OCI-Ly3 cells that 
carry a NF-κB activating CARD11 mutation (Figure 7B).5 Increased apoptotic 
changes were also observed in the mutated MYD88 cell lines and primary WM 
cells that showed decreased viability following ibrutinib, and more so A419259. In 
contrast, CC-292 had little or no impact on apoptosis in mutated MYD88 cells 
(Figure 7C). In as well, we observed little or no apoptotic activity for ibrutinib, 
A419259 or CC-292 apoptosis in MYD88WT cell lines or healthy donor B-cells 
(data not shown). To investigate whether ibrutinib or A419259 induced killing of 
WM cells was a consequence of BTK and/or HCK inhibition, we transduced 
MYD88L265P expressing BCWM.1 WM cells with a lentiviral control vector or 
vectors expressing wild-type BTK; BTK with a mutation of the cysteine required 
for irreversible inhibition (BTKC481S); wild-type HCK; or HCK with the gatekeeper 
mutation Thr333 (Thr338 based on c-SRC numbering).16 Transduction of BCWM.1 
WM cells with the BTK cysteine mutant (BTKC481S) but not the vector control or 
wild-type BTK resulted in decreased ibrutinib and CC-292 mediated killing of 
BCWM.1 WM cells (<1 log-fold shift) (Figure 7D). In contrast, treatment with HCK 
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inhibitor A419259 showed no survival change versus vector control transduced 
cells (Figure 7D).  
 
Transduction of BCWM.1 WM cells with the HCK gatekeeper mutant (HCKT333M; 
HCKT338M based on c-SRC numbering16) resulted in an >2 log-fold decrease in 
both ibrutinib and A419259 mediated tumor cell killing. Over-expression of wild-
type HCK also resulted in one log-fold decrease in both ibrutinib and A419259 
mediated mediated tumor cell killing when compared to control vector transduced 
BCWM.1 WM cells (Figure 7D). No substantial change in tumor cell killing 
following CC-292 treatment was observed in BCWM.1 cells transduced to express 
HCKT333M or wild-type HCK (Figure 7D). 
 
Discussion 
 
We sought to clarify the contribution of non-BTK target(s) to the activity of ibrutinib 
in MYD88 mutated diseases such as WM. We focused this study on HCK, a 
member of the SRC family of kinases. HCK is over-expressed at early stages of 
B-cell development, and its transcriptional regulation is suppressed with terminal 
B-cell differentiation.30,31 Using gene expression profiling, Guttierez et al12 
previously reported that HCK was highly over-expressed in malignant LPC taken 
from WM patients, though the genetic basis for this observation remained unclear. 
In this study, we observed that HCK was highly expressed in MYD88 mutated 
primary WM cells, WM and ABC-DLBCL cell lines, but was absent or expressed 
at low levels in healthy donor B-cells, as well as MYD88WT cell lines. Furthermore, 
we observed that over-expression of the MYD88L265P protein itself markedly 
induced HCK transcription across multiple B-cell lines, including both MYD88 
mutated and wild-type cell lines. It is not likely that HCK transcription was 
triggered by MYD88 triggered IL6, since exogenous treatment of MYD88 mutated 
WM cells with IL6 or an IL6 antibody did not directly impact HCK transcription. In 
addition CXCR4 mutations that are found in up to 40% of WM patients neither 
impacted HCK transcription or activation in primary WM cells, nor did we observe 
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HCK transactivation in previous studies with MYD88 mutated BCWM.1 and 
MWCL-1 cells that were transduced with CXCR4 WHIM mutated receptors and 
stimulated with CXCL12 (unpublished observations).32,33 Our findings therefore 
provide a genomic explanation for HCK over-expression in WM, and suggest that 
mutated MYD88 enforces high transcription levels of HCK. NF-kB, AP-1, and 
CREB binding sites are present on the promoter of HCK, and their transactivation 
is known to be triggered by wild-type MYD88 in response to TLR 
stimulation.32,33,34 Studies to delineate the precise signaling cascade(s) by which 
mutated MYD88 transduces HCK are therefore needed, though the constitutive 
activation of NF-kB by mutated MYD88 is a strong suspect in WM and ABC 
DLBCL cells, as well as AP-1 in ABC DLBCL.1,5,35 The B-cell receptor (BCR) and 
other pro-survival pathways may also contribute to HCK activation and warrant 
further investigation. 
 
The findings also suggest an important role for IL6 in triggering HCK activity in 
WM, and possibly other MYD88 mutated diseases. We show that both IL6 and 
IL6R are highly expressed in WM disease, and that MYD88 L265P itself induces 
IL6 transcription. Ngo et al5 showed that HCK and IL6 were among 285 genes 
whose transcription was down-regulated upon knockdown of MYD88 in HBL-1 
ABC-DLBCL cells that express L265P as a heterozygous mutation. The role of IL6 
as an activator of pHCK through IL6R/IL6ST has previously been reported, and 
appears dependent on an acidic domain (amino acids 771-811) of IL6ST.13,14 IL6 
is highly transcribed in WM and ABC-DLBCL tumors.12,36,37 IL6 is also secreted by 
the bone marrow microenvironment in response to WM cell adhesion.15 We show 
in these studies that HCK is hyper-activated in mutated MYD88 primary WM cells, 
as well as WM and ABC-DLBCL cell lines, and that exogenous IL6 induced its 
activation while knockdown of IL6ST attenuated HCK activation. HCK was also 
found to induce PI3K/AKT, MAPK/ERK, and BTK signaling, providing for the first 
time evidence that mutated MYD88 can trigger pro-survival signaling beyond its 
known activation of NFKB by eliciting HCK transcription and activation. The 
transactivation of BTK by HCK is also noteworthy. Cheng et al previously 
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described showed that BTK could bind to HCK through SH3 mediated 
interactions. In previous work, we described that the activated form BTK was 
complexed with MYD88 in MYD88 mutated cells, though the mechanism for BTK 
activation in this context remained unclear. Our findings offer a mechanistic 
explanation for BTK activation in MYD88 mutated WM and ABC DLCBL cells.  
 
A key finding of this study was the recognition of HCK as a novel therapeutic 
target for WM, and possibly other mutated MYD88 diseases. Kinase selectivity 
profiling had previously implicated HCK as a potential target of ibrutinib with an 
IC50 of 3.7 nM, a dose level close to the IC50 of BTK (0.5 nM) and well within the 
pharmacologically achievable levels of ibrutinib.11,38 We provide definitive 
evidence in this report that HCK is a target of ibrutinib using docking models, 
direct pull-down experiments with biotinylated ibrutinib, cellular target engagement 
and cellular rescue with inhibitor-resistant mutant proteins. We also observed that 
treatment of mutated MYD88 WM and ABC-DLBCL cells with ibrutinib or a 
preclinical HCK inhibitor (A419259) attenuated HCK activation, while over-
expression of wild-type HCK and more so HCK bearing a mutated gatekeeper 
(HCKT333M; HCKT338M based on c-SRC numbering)16 reduced the activity of both of 
these compounds in MYD88 mutated cells. The attenuation of MYD88 directed 
HCK activity may provide mechanistic insights into the high response activity 
observed in MYD88 mutated WM and ABC-DLBCL patients undergoing ibrutinib 
therapy.4,10 It also remains possible that mutations in the gatekeeper site of HCK 
could contribute to ibrutinib resistance, akin to that observed with BTKC481S 
mutations in CLL patients, and warrant examination.39 Finally, the potential to 
develop more potent HCK inhibitors is suggested by these findings. While ibrutinib 
suppressed HCK activity, higher levels of HCK suppression were observed with 
A419259, and were associated with greater levels of apoptosis in MYD88 mutated 
WM and ABC-DLBCL cells. Several scaffolds for targeted HCK inhibition are in 
development based on prior work implicating HCK in the pathogenesis of several 
solid and hematological malignancies, as well as productive HIV infection.40,41 In 
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addition to inhibiting other SRC family members, dasatinib also shows potent 
inhibition of HCK and may be active in diseases dependent on mutated MYD88.42  
 
In summary, our findings suggest that HCK is a downstream target of mutated 
MYD88, is activated by IL6, and triggers pro-survival signaling including 
PI3K/AKT, MAPK/ERK and BTK in MYD88 mutated cells. HCK is also a highly 
relevant target of ibrutinib, and represents a novel focus for therapeutic 
development in WM, and possibly other diseases driven by mutated MYD88. 
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Legends 
 
Figure 1. HCK transcription is driven by mutated MYD88.  
 
(A) HCK transcript levels in MYD88 mutated WM (BCWM.1, MWCL-1) and ABC 
DLBCL (TMD-8, HBL-1, OCI-Ly3, SU-DHL2) cells, and MYD88 wild-type (OCI-
Ly7 and OCI-Ly19 GCB DLBCL, Ramos Burkitt, MM1.S and RPMI-8226 
myeloma) cells by quantitative RT-PCR. (B) HCK transcription using TaqMan® 
Gene Expression Assay in primary lymphoplasmacytic cells (CD19+) from MYD88 
L265P expressing WM patients, and healthy donor derived non-memory 
(CD19+CD27-) and memory (CD19+CD27+) B-cells. p<0.01 for comparison of WM 
LPC versus either healthy donor non-memory or memory B-cells. (C) Fold change 
in HCK transcription following lentiviral transduction with vector control, Flag-
tagged MYD88 L265P or MYD88 wild-type protein in cell lines expressing mutated 
or wild-type MYD88. At the bottom of the Figure 1C, total Flag-tagged MYD88 
L265P or wild-type protein levels are shown for all transduced cell lines to 
demonstrate relative translation efficiency for MYD88 L265P and wild-type 
vectors, as well as GAPDH protein levels as protein loading controls.  
 
Figure 2. IL6 but not IL6R transcription is induced by mutated MYD88.  
 
Expression of IL6 (A) and IL6R (B) transcripts using TaqMan® Gene Expression 
Assays in MYD88 mutated and MYD88 wild-type (WT) cell lines. IL6 (C) and IL6R 
(D) transcript levels were also determined by TaqMan® Gene Expression Assays 
in primary lymphoplasmacytic cells (CD19+) from MYD88 L265P expressing WM 
patients, and healthy donor derived non-memory (CD19+CD27-) and memory 
(CD19+CD27+) B-cells. p<0.01 for comparison of IL6 or IL6R transcript levels in 
WM LPC versus either healthy donor non-memory or memory B-cells. IL6 (E) and 
IL6R (F) transcription following over-expression of MYD88 L265P or wild-type 
protein in cell lines expressing mutated or wild-type MYD88. Total Flag-tagged 
 25 
MYD88 L265P or wild-type protein, as well as GAPDH protein levels determined 
by immunoblotting are shown for all transduced cell lines in Figure 1C. 
 
Figure 3. HCK is hyperactive in MYD88 mutated cells, and its activation is 
triggered by IL6.  
 
(A) Results of PhosFlow analysis for phosphorylated HCK (pHCKTyr411) in MYD88 
mutated WM (BCWM.1, MWCL-1) and ABC DLBCL (TMD-8, OCI-Ly3) cells; 
MYD88 wild-type GCB DLBCL (OCI-Ly7, OCI-Ly19), Ramos Burkitt, and RPMI-
8226 myeloma cells. (B) Results of PhosFlow analysis for pHCKTyr411 in primary 
lymphoplasmacytic cells (CD20+) from 3 representative MYD88 L265P expressing 
WM patients, as well as non-memory (CD20+CD27-) and memory (CD20+CD27+) 
B-cells from healthy donors. Percentage of cells gating for pHCKTyr411 expression 
are shown in A and B. Histogram depicts the results of pHCKTyr411 expression in 
LPC derived from 20 WM patients, as well as non-memory and memory B-cells 
from 5 healthy donors. p<0.01 for comparison of p-HCK expression in WM LPC 
versus either healthy donor non-memory or memory B-cells. (C) pHCKTyr411 
expression in the presence or absence of IL6 (1 ng/mL) for 5 minutes in MYD88 
mutated (BCWM.1, MWCL-1, TMD-8, HBL-1, OCI-Ly3) and MYD88 wild-type 
(OCI-Ly7, OCI-Ly19, Ramos, RPMI 8226) cell lines, as well as primary WM 
lymphoplasmacytic cells. Peak pHCKTyr411 activation was determined by 
PhosFlow analysis after three MYD88 mutated cell lines were cultured with IL6 (1 
ng/mL) for 2, 5, and 15 minutes. (D) PhosFlow analysis of pHCKTyr411 in BCWM.1 
cells transduced with scrambled control vector or IL6ST knockdown vector 
(shRNA2) in the presence or absence of 1 ng/mL of IL6. 
 
Figure 4. HCK is a determinant of survival in MYD88 mutated cells. 
(A) HCK protein levels determined by western blot analysis and (B) survival 
determined by AlamarBlue® cell viability assay over a 9 day evaluation period in 
MYD88 mutated BCWM.1 and MWCL-1 WM cells, and TMD-8 and HBL-1 ABC 
DLBCL cells following transduction with inducible HCK knockdown (shRNA1, 
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shRNA2) or scrambled control vectors. Mean of two independent experiments is 
depicted for time points.  
 
Figure 5. HCK triggers pro-survival signaling in MYD88 mutated WM cells. 
(A) PhosFlow analysis for pHCKTyr411, pBTK, pAKT, and pERK in scramble control 
vector or HCK transduced MYD88 mutated BCWM.1 and MWCL-1 cells. (B) 
Impact of HCK over-expression or (C) HCK knockdown on PI3K/AKT (PIK3R2, 
AKT), MAPK (PLC1, ERK1/2), BTK (BTK, PLC2), and IRAK4 signaling in 
BCWM.1 and MWCL-1 cells using antibodies to detect phospho-specific and total 
protein expression by immunoblotting. GAPDH protein levels were determined for 
control purposes in all experiments. 
 
Figure 6. Ibrutinib binds to the ATP-binding pocket of HCK and blocks ATP 
binding.  
  
(A) Docking model of the Ibrutinib (purple stick) aligned with the co-crystal 
structure of HCK (green ribbon)-A419259 (yellow stick). The hydrogen bonds 
between the aminopyrimidine moiety of Ibrutinib and the hinge region of HCK are 
indicated. Docking studies showed that ibrutinib bound to the ATP-binding pocket 
of HCK with calculated affinity energy (ΔG) of -10.5 kcal/mol. (B) Results from 
pull-down experiments using streptavidin beads (SVB) and biotinylated ibrutinib 
(IB-BTN) and CC-292 (CC-BTN) to detect BTK and HCK binding in MYD88 
mutated BCWM.1, MWCL-1 and TMD-8 cells. (C) Results from kinase active-site 
inhibition assays utilizing an ATP-biotin (ATP-BTN) probe that was used to pull-
down active kinases in presence of ibrutinib, CC-292, or A419259 in lysates from 
BCWM.1 WM cells. 
 
Figure 7. HCK activity is blocked by ibrutinib and impacts survival of MYD88 
mutated WM cells.  
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(A) PhosFlow analysis showing changes in pHCKTyr411 following treatment of 
MYD88 mutated WM (BCWM.1, MWCL-1) and ABC DLBCL (TMD-8, OCI-Ly3, 
HBL-1) cells and MYD88 mutated primary lymphoplasmacytic cells from 4 WM 
patients with 0.5 uM of A419259, ibrutinib or CC-292 for 30 minutes. (B) Dose 
dependent survival determined by CellTiter-Glo® Luminescent cell viability assay 
for mutated (BCWM.1, MWCL-1, TMD-8, HBL-1, OCI-LY3) and wild type (OCI-
LY7, OCI-LY19, Ramos, RPMI 8226) MYD88 cells following treatment with 
ibrutinib, A419259 or CC-292 for 72 hours. (C) Apoptotic changes using propidium 
iodide (PI) and Annexin V (FITC-A) staining following treatment of mutated and 
wild type MYD88 cell lines, and primary lymphoplasmacytic cells from 3 WM 
patients with 0.5 uM of A419259, ibrutinib or CC-292 for 18 hours. DMSO denotes 
vehicle control only treated cells. Cell line results are from experiments performed 
in triplicate. Primary LPC data are from results obtained from 6 WM patients. (*) 
p<0.05 and (**) p<0.01 versus DMSO controls (D) Dose dependent tumor cell 
survival of MYD88 mutated BCWM.1 cells transduced with control vector or 
vectors expressing wild-type BTK (BTK WT); BTK expressing mutated site for 
ibrutinib binding (BTK C481S); wild-type HCK (HCK WT); or HCK expressing the 
gatekeeper mutation (HCKT333M; HCKT338M based on c-SRC numbering)16 and 
treated with ibrutinib, A419259 or CC-292. Protein levels following transduction 
with control, wild-type or mutated BTK or HCK vectors are also shown at the 
bottom of Figure 7D. 
 
 
 
 
 
 
 
 
 
 28 
Figure 1. 
 
 
 
 
 
 29 
Figure 2. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 30 
 
Figure 3. 
 
A. 
 
 
B. 
 
 
 
 
 
 
 31 
 
 
C. 
 
 
D. 
 
 
 
 
 
 
 
 
 32 
 
Figure 4. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 33 
 
Figure 5. 
 
A. 
 
 
 34 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 35 
Figure 6. 
 
 
 
 
 
 
 
 
 
C. 
SVB 
IP: ATP-biotin 
IB: BTK 
IB: HCK 
IB: SRC 
ATP-BTN 
Compounds (µM) 
 
  ─       ─      10     1.0     0.1 
  ─       +       +        +       + 
  +       +       +        +        + 
+ Ibrutinib + A419259 
IB: LYN 
+ AVL-292 
  ─       ─      10     1.0     0.1 
  ─       +       +        +       + 
  +       +       +        +        + 
  ─       ─      10     1.0     0.1 
  ─       +       +        +       + 
  +       +       +        +        + 
input 
input 
input 
input 
. 
 +Ibrutinib                +CC-292                +A419259 
 36 
Figure 7. 
 
A. 
 
 
 
 
 
 
 
 
 37 
 
 
 
 
 
 
 
B. 
 38 
C. 
 
 
 
 
 
 
 39 
 
 
 
 
 
 
 
 
